Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 10:30 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 817–840 of 17,016 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Elevate Clear all
Active, not recruiting Phase 4 Interventional

Women's IschemiA TRial to Reduce Events In Non-ObstRuctive CAD

NCT03417388
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
High dose potent statin, ACE-I (lisinopril) or ARB (losartan), Aspirin 81 enteric coated tablet daily, Lifestyle Counseling, Quality of Life Questionnaires
Drug · Behavioral
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 100 Years · Female only
Enrollment
2,476 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
80
States / cities
Mobile, Alabama • Gilbert, Arizona • Phoenix, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Oct 30, 2026, 10:30 PM EDT
Terminated Phase 1 Interventional

Continued Treatment for Participants Enrolled in Studies of BXQ-350

NCT04404569
View directory record Official record
Conditions
Neoplasms
Interventions
BXQ-350
Drug
Lead sponsor
Bexion Pharmaceuticals, Inc.
Industry
Eligibility
1 Year and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
3
States / cities
Lexington, Kentucky • Cincinnati, Ohio • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 20, 2024 · Synced Oct 30, 2026, 10:30 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Human Tick Kill Study to Investigate the Safety, Tolerability, and Whole Blood Concentration of TP-05

NCT05387083
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Low Dose TP-05, High Dose TP-05, Placebo Comparator
Drug
Lead sponsor
Tarsus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 59 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 30, 2026, 10:30 PM EDT
Completed No phase listed Observational

Risk Factors for Developing a Blood Clot in Patients Who Are Undergoing Cancer Treatment for Newly Diagnosed Gliomas

NCT00253669
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Thromboembolism
Interventions
laboratory biomarker analysis, physiologic testing, management of therapy complications
Other · Procedure
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 120 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
9
States / cities
Birmingham, Alabama • Tampa, Florida • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2018 · Synced Oct 30, 2026, 10:30 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma

NCT00602641
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Laboratory Biomarker Analysis, Lenalidomide, Melphalan, Prednisone, Quality-of-Life Assessment, Thalidomide
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2027
U.S. locations
389
States / cities
Mobile, Alabama • Scottsdale, Arizona • Fort Smith, Arkansas + 255 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 30, 2026, 10:30 PM EDT
Completed Not applicable Interventional

Establishing Lymphedema and Fibrosis Measures in Oral Cancer Patients

NCT02412241
View directory record Official record
Conditions
Oral Cavity Cancer, Oropharyngeal Cancer, Lymphedema, Fibrosis
Interventions
LEF measures, Technical measure
Other · Procedure
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
21 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 3, 2021 · Synced Oct 30, 2026, 10:30 PM EDT
Active, not recruiting Not applicable Interventional

Psoriatic Arthritis D2P Screening

NCT04110522
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Direct to patient PsA Screening Questionnaire
Other
Lead sponsor
Jessica Walsh
Other
Eligibility
18 Years and older
Enrollment
18,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 30, 2026, 10:30 PM EDT
Completed Phase 2 Interventional Results available

Allo-HCT MUD for Non-malignant Red Blood Cell (RBC) Disorders: Sickle Cell, Thal, and DBA: Reduced Intensity Conditioning, Co-tx MSCs

NCT00957931
View directory record Official record
Conditions
Sickle Cell Disease, Thalassemia, Diamond-Blackfan Anemia
Interventions
Bone marrow transplantation, Mesenchymal Stromal Cells
Procedure · Biological
Lead sponsor
Stanford University
Other
Eligibility
1 Year to 25 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
2
States / cities
Birmingham, Alabama • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 6, 2018 · Synced Oct 30, 2026, 10:30 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of PK of AC1204 v Caprylic Triglyceride Oil Incl Food Effect on Ketone Body Production

NCT02747602
View directory record Official record
Conditions
Healthy
Interventions
AC-1204, caprylic triglyceride oil (standard breakfast), caprylic triglyceride oil (high fat breakfast)
Drug
Lead sponsor
Cerecin
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 28, 2016 · Synced Oct 30, 2026, 10:30 PM EDT
Not listed No phase listed Observational

Prediabetes and Type 2 Diabetes Data Collection Study

NCT04503239
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Pre-diabetes
Interventions
G6
Device
Lead sponsor
DexCom, Inc.
Industry
Eligibility
18 Years and older
Enrollment
306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
5
States / cities
Lemon Grove, California • Las Vegas, Nevada • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2021 · Synced Oct 30, 2026, 10:30 PM EDT
Completed Phase 3 Interventional Results available

High Dose Preoperative Cholecalciferol Supplementation and Perioperative Vitamin D Status

NCT01689779
View directory record Official record
Conditions
Hypovitaminosis D
Interventions
100,000 IU cholecalciferol, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 28, 2017 · Synced Oct 30, 2026, 10:30 PM EDT
Recruiting Phase 2 Interventional

Propranolol for Aggression, Self-Injury, and Severe Disruptive Behavior in Adolescents and Adults With Autism

NCT07091279
View directory record Official record
Conditions
Autism Spectrum Disorder, Challenging Behaviour, Aggression, Severe Disruptive Behaviour Disorders, Self-injury
Interventions
Propranolol, Placebo
Drug
Lead sponsor
Jeremy Veenstra-vanderweele
Other
Eligibility
12 Years to 40 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Staten Island, New York • White Plains, New York
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 30, 2026, 10:30 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Protein and Resistance Exercise to Stop Sarcopenic Obesity Now

NCT04014296
View directory record Official record
Conditions
Obesity
Interventions
High Protein Diet Counseling, Resistance Training Counseling, Intensify Initial Intervention, Combined Supplement and Supervised Resistance Training
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
50 Years and older
Enrollment
89 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 30, 2026, 10:30 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Dime La VerDAD: Verify, Debunk, and Disseminate

NCT06417762
View directory record Official record
Conditions
Influenza, COVID-19, Communication Research, Health Behavior, Respiratory Viral Infection
Interventions
Science Communication Curriculum Cohort 1, Science communication curriculum Cohort 2, Science communication curriculum Cohort 3, Science communication curriculum Cohort 4
Behavioral
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 99 Years
Enrollment
1,400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
4
States / cities
Chicago, Illinois • Iowa City, Iowa • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 30, 2026, 10:30 PM EDT
Completed Phase 2 Interventional Results available

A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has Spread

NCT02060188
View directory record Official record
Conditions
Microsatellite Unstable Colorectal Cancer, Microsatellite Stable Colorectal Cancer, Mismatch Repair Proficient Colorectal Cancer, Mismatch Repair Deficient Colorectal Cancer
Interventions
Ipilimumab, Nivolumab, Cobimetinib, Daratumumab, BMS-986016
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
385 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
14
States / cities
Gilbert, Arizona • Los Angeles, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2025 · Synced Oct 30, 2026, 10:30 PM EDT
Completed Phase 3 Interventional Results available

Pharmacokinetic and Pharmacodynamic Study of High-Dose Rifapentine and Moxifloxacin for Treatment of Tuberculosis

NCT02563327
View directory record Official record
Conditions
Tuberculosis
Interventions
Rifapentine, Moxifloxacin, Rifampin, Isoniazid, Pyrazinamide, Ethambutol, Pyridoxine
Drug · Dietary Supplement
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
18 Years and older
Enrollment
2,516 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 30, 2026, 10:30 PM EDT
Not yet recruiting Not applicable Interventional

Simplifying Diet Tracking in a Digital Weight Loss Intervention

NCT07601061
View directory record Official record
Conditions
Overweight, Obesity, Weight Loss, Health Behavior, Lifestyle Intervention
Interventions
Simplified Dietary Self-Monitoring, Detailed Dietary Self-Monitoring, Core Behavioral Weight Loss Intervention
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
328 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2030
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 30, 2026, 10:30 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Digitally Enhanced Stepped-Care for Depression in Primary Care

NCT07634705
View directory record Official record
Conditions
Depression
Interventions
Behavioral Activation Therapy App, Telehealth Delivered Behavioral Activation
Behavioral
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 30, 2026, 10:30 PM EDT
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

The Optimization and Evaluation of the Extremism and Intolerance Curriculum for the Kingdom of Bahrain.

NCT05088694
View directory record Official record
Conditions
Norm, Social, Literacy, Resistance Skills, Beliefs About Consequences, Decision Making Skills, Empathy, Tolerance, Open Mindedness, Active Citizenship, Anti-extremism
Interventions
Peaceful Coexistence
Behavioral
Lead sponsor
University of North Carolina, Greensboro
Other
Eligibility
11 Years to 18 Years
Enrollment
1,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Greensboro, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 18, 2024 · Synced Oct 30, 2026, 10:30 PM EDT
Terminated Phase 2 Interventional Results available

Study of Efficacy and Safety of MIJ821 in Addition to Comprehensive Standard of Care on the Rapid Reduction of Symptoms of Major Depressive Disorder in Subjects Who Have Suicidal Ideation With Intent

NCT04722666
View directory record Official record
Conditions
Major Depressive Disorder With Suicidal Ideation With Intent
Interventions
MIJ821 Intravenous Injection, Placebo Intravenous Injection
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
6
States / cities
Birmingham, Alabama • Farmington, Connecticut • Oakland Park, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 30, 2026, 10:30 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety and Immunogenicity of an Adjuvanted RSV Vaccine in Healthy Older Adults

NCT03572062
View directory record Official record
Conditions
Respiratory Tract Infection
Interventions
Formulation A, Formulation B, Formulation C, Placebo
Biological
Lead sponsor
Pfizer
Industry
Eligibility
65 Years to 85 Years
Enrollment
317 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
4
States / cities
South Miami, Florida • Peoria, Illinois • Fremont, Nebraska + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2021 · Synced Oct 30, 2026, 10:30 PM EDT
Completed Phase 2 Interventional Results available

Temozolomide & RT Followed by Dose Dense vs Temozolomide & Retinoic Acid in Pts w/Glioblastoma

NCT00200161
View directory record Official record
Conditions
Glioblastoma, Gliomas
Interventions
Temozolomide
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2017
U.S. locations
3
States / cities
Basking Ridge, New Jersey • Commack, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 7, 2018 · Synced Oct 30, 2026, 10:30 PM EDT
Completed Phase 2 Interventional

Peripheral Stem Cell Transplantation Plus Combination Chemotherapy in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

NCT00003402
View directory record Official record
Conditions
Leukemia, Lymphoma
Interventions
carmustine, cisplatin, cyclophosphamide, dexamethasone, etoposide, melphalan, paclitaxel, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation
Drug · Procedure
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 70 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2002
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 17, 2019 · Synced Oct 30, 2026, 10:30 PM EDT
Completed Phase 2 Interventional

Folate Receptor Alpha Peptide Vaccine With GM-CSF in Patients With Triple Negative Breast Cancer

NCT02593227
View directory record Official record
Conditions
Breast Cancer
Interventions
Low dose FRα vaccine, Cyclophosphamide, High dose FRα vaccine
Biological · Drug
Lead sponsor
Marker Therapeutics, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
11
States / cities
Tampa, Florida • Westwood, Kansas • Baltimore, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2021 · Synced Oct 30, 2026, 10:30 PM EDT